

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **VOLUNTARY ANNOUNCEMENT**

### **FIRST PATIENT DOSED IN A PHASE II CLINICAL TRIAL OF KN026 COMBINED WITH PALBOCICLIB AND FULVESTRANT FOR THE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER**

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The Board is pleased to announce that the first patient has been successfully dosed in a phase II clinical trial of KN026 (“**KN026-205**”). KN026-205 is a multi-center and open-label phase II clinical trial designed to evaluate the efficacy, safety and tolerability of KN026 in combination with Ibrance® (palbociclib), which is developed by Pfizer Inc. (New York Stock Exchange ticker symbol: PFE), and fulvestrant, in the treatment of locally advanced unresectable or metastatic HER2-positive breast cancer in patients who have failed treatment of Trastuzumab and Taxanes. This trial targets to enroll 36 subjects and the primary endpoint is the objective response rate assessed in accordance with RECIST v1.1.

#### **ABOUT KN026**

KN026 was designed to be a global-level next-generation HER2-targeted therapy. With its innovative structure, it binds simultaneously to 2 distinct clinically validated epitopes of HER2 (paratope II and IV), and maintains a wild type Fc region. This results in (i) a dual blockade of HER2-related signaling pathways, (ii) strengthened binding to HER2 receptors, (iii) a reduction of HER2 proteins on the cell surface, and (iv) increased tumor killing effect through intact antibody-dependent cell-mediated cytotoxicity. These binding mechanisms enable KN026 to have excellent tumor suppressive effect. Several phase I/II clinical trials of KN026 have shown good preliminary efficacy in patients with advanced HER2-positive breast cancer and gastric cancer/gastroesophageal junction cancer. Currently, the pivotal clinical trial of KN026 combined with chemotherapy in patients with HER2-positive gastric cancer (including gastroesophageal junction cancer) who have failed first-line treatment is being conducted in China.

## **ABOUT THE COMPANY**

The Company is a leading clinical-stage biopharmaceutical company in China with a fully-integrated proprietary biologics platform in bispecific antibody and protein engineering. Differentiated in-house pipeline of the Company includes the oncology drug candidates with one approved for marketing by the National Medical Products Administration of China, three in late clinical stage, and three that have received IND approval or in schedule for the IND submission. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological new drug candidates that could potentially benefit patients globally.

## **DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS**

“Board”	The board of directors of the Company
“COVID-19”	coronavirus disease, an infectious disease caused by the most recently discovered coronavirus (severe acute respiratory syndrome coronavirus 2), first reported in December 2019
“CTLA-4”	cytotoxic T-lymphocyte-associated protein 4
“fulvestrant”	a drug used to treat certain types of breast cancer
“HER2”	human epidermal growth factor receptor 2
“IND”	investigational new drug
“palbociclib”	a medication for the treatment of HR-positive and HER2-negative breast cancer developed by Pfizer Inc.
“RECIST v1.1”	Response Evaluation Criteria in Solid Tumors, a standard way to measure the response of a tumor to treatment
“Taxanes”	a class of diterpene alkaloids with anticancer activity
“the U.S.” or “the United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“Trastuzumab”	a monoclonal antibody used to treat breast cancer and stomach cancer

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to develop, or ultimately market, KN026 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, May 26, 2022

*As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. Guo Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.*